

PREScription DRUG AFFORDABILITY ADVISORY COUNCIL CONFLICTS OF INTEREST DISCLOSURES

The following members of the Advisory Council have disclosed a personal association with an eligible drug or a financial conflict of interest with respect to a drug manufacturer, for themselves or for an immediate family member. With respect to a drug manufacturer or specific drug, there are potential conflicts of interest with the eligible drugs under consideration by the Prescription Drug Affordability Board (attached) as specified below.

GAIL DEVORE: Fiasp (NovoNordisk is the manufacturer), Novolog (NovoNordisk is the manufacturer), Ezetemibe, Welbutrin (generic), Acyclovir Dexcom CGM, Sensor, Terazol, Omnipod Dash pods, Mounjaro (Lilly is the manufacturer), Victoza, Testosterone, Humira, Adderall, Adderall XR, Belsomra, Inderal LA, Clindagel, Clobetasol, Desonide, Retin-A, Diclofenac.

DR. BOB MULCH: Abbvie, Astellas, Abbott Labs, Amgen, Bayer, ADR, Bristol-Myers, Chugai Pharm, Genmab, GSK, Johnson & Johnson, Eli Lilly, Merck, Vertex Pharm, Takeda, Sanofi, Regeneron, Roche, Novartis, Gilead, Hydrochlorothiazide, and Valsartan.

NATHAN WILKES: Alecensa, Cotellic, Enspryng, Erivedge, Esbriet, Evrysdi, Helimbra, Herceptin, Kadcyla, Novoseven, Nutropin AQ NuSpin, Ocrevus, Perjeta, Rozlytrek, Tecentriq, Venclexta, and Zelboraf.

DR. RICHARD MIRANDA: Risankizumab.

DR. BRETT McQUEEN: Actemba, Activase, Alecensa, Cotellic, Emend, Enspryng, Erivedge, Esbriet, Evrysdi, Fosiprepitant Dimeglumine, Gazyva, Helimbra, Herceptin, Hycela, Kadcyla, Keytruda, Koselugo, Lenvima, Lucentis, Lynparza, Mavenclad, Nutropin AQ NuSpin, Ocrevus, Ontruzant, Perjeta, Polivy, Recarbrio, Rozlytrek, Sivextro, Tecentriq, Venclexta, Welireg, Zelboraf, Merck, Genetech, Sanofi, and Atorvastatin.

DR. INGRID PAN: Pharming Group N.V., Sobi Pharmaceuticals, Joenja, and Gamifant.

In addition, INGRID PAN discloses that she has authored the following research papers:

- Pan I, Shah P, Singh J, Kelly KN, Bondi D. Comparison of neonatal outcomes with and without prophylaxis with indomethacin in premature

neonates. J Pediatr Pharmacol Ther. 2021 July 1;26(5):478-483.
doi: <https://doi.org/10.5863/1551-6776-26.5.478>.

- Pan I, Lin C, Palestine A, Jung J. Efficacy and Safety of Tacrolimus for the Treatment of Pediatric Noninfectious Uveitis [abstract]. J Am Coll Clin Pharm. 2021;12(12):1707-1708. Abstract no 173. DOI: 10.1002/jac5.1561
- Vallejos C, Cooper J, Pan I. Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment [abstract]. Arthritis Rheumatol. 2023; 75(S9):711-12. Abstract no 0359.
<https://doi.org/10.1002/art.42700>.
- White S, Morrow R, Pan I, de Zoeten EF. Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists. J Pediatr Gastroenterol Nutr. 2023 Mar 6. doi: 10.1097/MPG.0000000000003757.
- Reidy M, Pan I, Cramer J, Garrity L. Navigating clinical and operational challenges of adeno-associated virus gene therapy: A guide for pharmacists. J Am Coll Clin Pharm. 2025; doi: 10.1002/jac5.70036.

INGRID PAN also disclosed that she has peer reviewed the following research articles:

- American College of Clinical Pharmacy Pediatric Self-Assessment Program. Book Title: Ambulatory Care and Hematology. March 2021.
- Updates in Therapeutics: Pediatric Pharmacy Preparatory Review and Recertification Course. Chapter: Immunology. March 2022.
- American College of Clinical Pharmacy 2022 Clinical Reasoning Series – Pediatric Program. September 2022.
- American College of Clinical Pharmacy Ambulatory Care Self-Assessment Program. Book Title: Geriatric and Pediatric Care. Chapter Title: Rheumatology: Juvenile Arthritis. February 2023.
- 2023 Pediatric Pharmacy Preparatory Review and Recertification Course. Chapter: Immunology. December 2023.
- American College of Clinical Pharmacy Pediatric Self-Assessment Program. Book Title: Oncology and Hematology Disorders. Chapter Title: Allogenic Bone Marrow Transplant. May 2024.

KATELIN LUCARIELLO: Benefix, Besponsa, Bosulif, Braftovi, Daurismo, Fragmin, Genotropin, Ibrance, Inflectra, Inlyta, Lorbrena, Mektovi, Oxbryta, Panzyga, Silvadene, Somavert, Sutent, Talzenna, Vyndamax, Vyndaqel, Xalkori, Xtandi, Xyntha Solofuse, and Xyntha.

In addition, KATELIN LUCARIELLO discloses that she is a representative of PhRMA and has a general conflict with the following pharmaceutical manufacturers and with brand name drugs/ biological products that are manufactured by the

following PhRMA members: Alkermes, Amgen, Astellas, AstraZeneca, Bayer, BioMarin, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Daiichi Sankyo, Eisai, Eli Lilly, EMD Serono, Genentech, Genmab, Gilead, GlaxoSmithKline, Incyte, Ipsen, Johnson & Johnson, Lundbeck, Merck, Neurocrine, Novartis, Novo Nordisk, Otsuka, Pfizer, Sanofi, Takeda, and UCB.

LEAH LINDAHL: Alprazolam, Atenolol, Botox, and Dapsone.

In addition, LEAH LINDAHL discloses that she currently works for the Healthcare Distribution Alliance (HDA), the national trade association representing primary pharmaceutical wholesale distributors. The members provide logistics and distribution services for pharmaceutical manufacturers operating in the U.S., which are also affiliated with HDA.

Finally, all Advisory Council members have been appointed on the basis of their positions as stakeholders with personal experience, professional expertise, or both, in the realm of prescription drugs.

The remaining Advisory Council members—Kim Bimestefer, Dr. Kimberley Jackson, Sarita Parikh, Marc Reese, and Fayez Azeez—have disclosed that they have no potential conflicts of interest with respect to the eligible drugs or their manufacturers.

Dated May 19, 2025